Today: 9 June 2026
Firefly Aerospace Stock Jumps After Q1 Revenue Beat and Golden Dome Defense Deal

Firefly Aerospace Stock Jumps After Q1 Revenue Beat and Golden Dome Defense Deal

CEDAR PARK, Texas, May 4, 2026, 17:03 CDT

Firefly Aerospace Inc. shares rose about 10% in extended trading on Monday after the space and defense company reported record first-quarter revenue and kept its 2026 sales outlook intact. The stock was quoted at $36.69 after the close, after ending regular trading at $33.37.

The move matters because investors are still testing whether Firefly can turn launch contracts, lunar missions and missile-defense software into steady revenue. The company posted $80.9 million in revenue for the quarter ended March 31, up 40% from the prior quarter, but its net loss widened to $96.7 million from $60.1 million a year earlier.

The adjusted loss was 46 cents a share, better than the 50-cent loss expected by analysts surveyed by Zacks Investment Research. Revenue also beat the $73.8 million estimate from four analysts in that survey. Adjusted figures strip out certain one-time or non-cash items, and can differ from losses calculated under standard accounting rules.

Firefly said it still expects 2026 revenue of $420 million to $450 million. Chief Executive Jason Kim said the quarter brought “another quarterly revenue record” and pointed to Blue Ghost lunar milestones, Alpha Flight 7 and work tied to the U.S. Space Force. Firefly Aerospace

The company also disclosed fresh defense work. SciTec, a Firefly subsidiary, received an Other Transaction Authority agreement from U.S. Space Force Space Systems Command for the Space-Based Interceptor program, part of the Golden Dome missile-defense architecture. An OTA is a more flexible government procurement tool often used to speed prototype and technology work.

Space Systems Command said it had awarded 20 OTA agreements to 12 companies with potential combined value of up to $3.2 billion, aimed at developing a low-Earth-orbit interceptor layer by 2028. The program is meant to counter ballistic, hypersonic and cruise-missile threats.

SciTec President David Simenc said the deal came at a “pivotal moment for national defense.” The Princeton, New Jersey-based unit has supported U.S. defense and intelligence customers for more than 45 years in missile warning, data fusion and space-domain awareness, Firefly said. GlobeNewswire

The award also puts Firefly-owned SciTec in a pool with much larger defense names. Space Systems Command listed Lockheed Martin, Northrop Grumman and Raytheon among the companies receiving Space-Based Interceptor OTA awards.

Analysts had framed launch cadence as the key test before the results. Cantor Fitzgerald analyst Colin Canfield wrote that Firefly’s target of four Alpha launches in 2026 looked “achievable,” while Goldman Sachs analyst Noah Poponak kept a Neutral rating and flagged questions around “growth, margins and cash flow.” Investing.com

Firefly said Alpha Flight 7 completed its mission objectives, including Block II subsystem validation and deployment of a Lockheed Martin demonstrator payload. It also cited a $109 million engineering change proposal under the Space Force’s FORGE Enterprise OPIR Services contract, tied to missile-warning data-center delivery.

But the quarter was not clean. Loss from operations widened to $95.7 million from $58.5 million, and free cash flow — operating cash after capital spending — was negative $78.9 million. Firefly also warned that delayed or failed launches, manufacturing limits, government funding changes and regulatory approvals could alter its outlook.

For now, the market is giving Firefly credit for revenue growth and defense exposure. The harder question is still the same one: whether it can launch more often, keep lunar work on schedule and slow the cash burn before the next round of earnings.

Stock Market Today

  • Pfizer Shares Drop Premarket Despite New FDA Approval for Hemophilia Drug
    June 9, 2026, 9:26 AM EDT. Pfizer shares declined 1.7% premarket to $25.62 following FDA approval of an expanded label for its hemophilia treatment Hympavzi, now authorized for patients aged 6 and older, including those with inhibitors-antibodies reducing clotting-factor therapy effectiveness. The drug offers a weekly subcutaneous injection alternative to frequent intravenous infusions. Despite the regulatory win, investor focus remains on Pfizer's obesity drug berobenatide, a monthly GLP-1 receptor agonist, competing with Novo Nordisk and Eli Lilly in weight loss treatments. Pfizer reported Q1 revenue of $14.5 billion, up 2% operationally, maintaining 2026 guidance of $59.5-$62.5 billion revenue and $2.80-$3.00 adjusted earnings per share, though earnings fell to 75 cents. Market reaction reflects caution over the company's longer path to profit growth amid patent expirations and competition.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Stock Market Today: Dow Sinks 557 Points as Oil Shock Tests Wall Street’s Record Run
Previous Story

Stock Market Today: Dow Sinks 557 Points as Oil Shock Tests Wall Street’s Record Run

Dow Drops 557 Points as Oil Shock Hits US Stocks; Palantir Slides After Hours
Next Story

Dow Drops 557 Points as Oil Shock Hits US Stocks; Palantir Slides After Hours

Go toTop